Adamis Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Adamis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adamis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Adamis Pharmaceuticals saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 4,130,000 shares, a decline of 18.5% from the January 28th total of 5,070,000 shares. Based on an average trading volume of 18,730,000 shares, the days-to-cover ratio is currently 0.2 days.
View Adamis Pharmaceuticals' Short Interest.

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Adamis Pharmaceuticals.

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its quarterly earnings results on Saturday, November, 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The specialty pharmaceutical company had revenue of $4.30 million for the quarter, compared to the consensus estimate of $8.15 million. Adamis Pharmaceuticals had a negative net margin of 188.31% and a negative trailing twelve-month return on equity of 99.57%.
View Adamis Pharmaceuticals' earnings history.

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADMP shares have increased by 119.5% and is now trading at $0.8845.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1-year price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.50. On average, they expect Adamis Pharmaceuticals' share price to reach $1.25 in the next year. This suggests a possible upside of 41.3% from the stock's current price.
View analysts' price targets for Adamis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Adamis Pharmaceuticals include Evelo Biosciences (EVLO), Lotus Pharmaceuticals (LTUS), Summit Therapeutics (SMMT), Affimed (AFMD), Wave Life Sciences (WVE), Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), Mirum Pharmaceuticals (MIRM), Syros Pharmaceuticals (SYRS), Spero Therapeutics (SPRO), 89bio (ETNB), Kala Pharmaceuticals (KALA), Orphazyme A/S (ORPH), Aldeyra Therapeutics (ALDX) and Puma Biotechnology (PBYI).
View all of ADMP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Adamis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.57%) and Verdence Capital Advisors LLC (0.06%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends for Adamis Pharmaceuticals.

ADMP stock was sold by a variety of institutional investors in the last quarter, including Verdence Capital Advisors LLC. Company insiders that have sold Adamis Pharmaceuticals company stock in the last year include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins, and Ronald B Moss.
View insider buying and selling activity for Adamis Pharmaceuticals or view top insider-selling stocks.

ADMP stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Adamis Pharmaceuticals or or view top insider-buying stocks.

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMP stock can currently be purchased for approximately $0.88.

Adamis Pharmaceuticals has a market capitalization of $118.70 million and generates $22.11 million in revenue each year. The specialty pharmaceutical company earns $-29,310,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Adamis Pharmaceuticals employs 131 workers across the globe.

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]